Lakefront Biotherapeutics (GLPGF) EPS (Basic) Growth (3y) (2017 - 2026)
Powered by 
Analysis
Lakefront Biotherapeutics (GLPGF) EPS (Basic) Growth (3y) (2017 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.55 Bn | 197.56 Bn | 7.24 Bn | 19.50% |
| 2 | Gilead Sciences | 181.17 Bn | 177.99 Bn | 6.22 Bn | -129.90% |
| 3 | Vertex Pharmaceuticals | 132.18 Bn | 124.33 Bn | 2.84 Bn | 6.85% |
| 4 | Regeneron Pharmaceuticals | 82.50 Bn | 74.50 Bn | 3.93 Bn | 11.71% |
| 5 | Argenx Se | 61.66 Bn | 56.48 Bn | 1.37 Bn | 86.03% |
| 6 | Moderna | 54.61 Bn | 49.47 Bn | 52.00 Mn | 18.44% |
| 7 | Alnylam Pharmaceuticals | 34.17 Bn | 30.86 Bn | 992.69 Mn | 36.73% |
| 8 | Biogen | 31.36 Bn | 30.07 Bn | 1.96 Bn | -45.60% |
| 9 | Roivant Sciences | 30.04 Bn | 30.04 Bn | 1.16 Mn | - |
| 10 | Lakefront Biotherapeutics | 1.73 Bn | 1.73 Bn | 3.51 Mn | -332.82% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -332.82% |
| Mar 31, 2026 | -12.10% |
| Dec 31, 2025 | 1,069.07% |
| Sep 30, 2025 | -205.99% |
| Jun 30, 2025 | 119.83% |
| Mar 31, 2025 | -120.61% |
| Dec 31, 2024 | 977.94% |
| Sep 30, 2024 | 16.62% |
| Jun 30, 2024 | 39.77% |
| Mar 31, 2024 | 102.07% |
| Dec 31, 2023 | 917.01% |
| Sep 30, 2023 | 45.39% |
| Jun 30, 2023 | 26.08% |
| Mar 31, 2023 | 33.72% |
| Dec 31, 2022 | 53.28% |
| Sep 30, 2022 | -64.96% |
| Jun 30, 2022 | 32.74% |
| Mar 31, 2022 | 40.10% |
| Dec 31, 2021 | -70.20% |
| Sep 30, 2021 | -115.36% |